<DOC>
	<DOCNO>NCT02347228</DOCNO>
	<brief_summary>The objective Phase I study determine maximum tolerable dose ( MTD ) evaluate pharmacokinetics ( PK ) , safety/ tolerability - preliminary efficacy OB318 patient advance solid malignancy .</brief_summary>
	<brief_title>Evaluate Safety , Tolerability , PK , Preliminary Clinical Activity OB318 Patients With Advanced Solid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>1 . Male female patient age ≥20 year 2 . Pathologically cytologically confirm advanced solid tumor standard therapy proven provide clinical benefit exist longer effective . 3 . Evaluable disease , either least one measurable untreated target lesion image RECIST 1.1 ( Response Evaluation Criteria Solid Tumors ) criteria measurable informative tumor marker ( ) . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance score ≤ 2 . 5 . Life expectancy ≥ 3 month . 6 . If history brain metastasis treat radiation therapy , radiation therapy require complete least 3 month prior enrolment metastasis achieve stable disease ( SD ) since radiation completion . 7 . Must recover toxicity previous anticancer treatment NCICTCAE grade 1or low , except alopecia . 8 . Laboratory value screen : Absolute neutrophil count ≥ 1,500 /mm3 ; Platelets ≥ 75,000 /mm3 ; Hemoglobin ( Hb ) ≥ 8.5 g/dL ; Total bilirubin ≤2.0 mg/dL ; AST ( SGOT ) ≤ 3 × ULN ( upper limit normal ) ; ALT ( SGPT ) ≤ 3 × ULN ; Serum creatinine ≤1.5 mg/dL measure creatinine clearance ≥ 60 mL/min . 9 . Patients primary liver cancer hepatic metastasis eligible enroll , provide , screen , follow criterion meet : Total bilirubin ≤2.0 mg/dL ; AST ALT ≤ 5 × ULN ; ChildPugh Class A ; Patients history esophageal bleed varix sclerosed banded bleeding episode occur prior 6 month . 10 . Female patient must either nonchildbearing potential , i.e . surgically sterilize one year postmenopausal ; , childbearing potential , confirm pregnant screening must use adequate contraceptive precaution ( per investigator ) entire treatment period study 6 month exit study . 11 . Male patient female partner childbearing potential must willing use reliable form contraception ( per investigator ) , screen 6 month exit study . 12 . Given sign dated write informed consent willing/able comply protocol require visits/procedures 1 . Primary major surgery &lt; 4 week prior plan first study treatment day . 2 . Lactating pregnant woman plan become pregnant . 3 . Except alopecia , drugrelated AE previous treatment recover grade 1 less prior plan first study treatment day . 4 . With active systemic infection , active clinically significant cardiac disease , active gastrointestinal disease , active pulmonary disease , medical condition may significantly affect adequate absorption investigational product , eg. , bad nutrition , proteinuria , etc.. 5 . Previous malignancy , except basalcell carcinoma skin carcinomainsitu uterine cervix , unless tumor treat curative intent 2 year prior study entry . 6 . Known allergic OB318 formulation excipients . 7 . History autoimmune disease . 8 . Taking anticoagulant antiplatelet drug ( eg aspirin , Coumadin , ginko , clopidogrel ) . 9 . Use investigational agent nonregistered product within 4 week baseline . 10 . Known human immunodeficiency virus ( HIV ) positivity . 11 . With condition , judge investigator , unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>OB318</keyword>
	<keyword>Advanced Solid Malignancies</keyword>
	<keyword>Antrodia cinnamomea</keyword>
	<keyword>Antrodia camphorata</keyword>
</DOC>